NPS PHARMACEUTICALS INC
SC 13D/A, 1997-12-24
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CORPORATE RENAISSANCE GROUP INC, 10-K, 1997-12-24
Next: SPORTMART INC, DEFR14A, 1997-12-24



<PAGE>
 
                      SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, DC  20549

                                ---------------

                                 SCHEDULE 13D
                                (RULE 13d-101)

                   UNDER THE SECURITIES EXCHANGE ACT OF 1934
                             (AMENDMENT NO. 1)/1/


                           NPS PHARMACEUTICALS, INC.
                           -------------------------
                               (Name of Issuer)

                                 Common Stock
                                 ------------
                        (Title of Class of Securities)

                                  62936 P 103
                                  -----------
                                (CUSIP Number)

                                  Hope Flack
                               BVF Partners L.P.
                       333 West Wacker Drive, Suite 1600
                           Chicago, Illinois  60606
                                (312) 263-7777
                 --------------------------------------------
                 (Name, Address and Telephone Number of Person
               Authorized to Receive Notices and Communications)

                              December 1, 1997
                              -------------------
            (Date of Event which Requires Filing of this Statement)

     If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].

          Note: Six copies of this statement, including all exhibits, should be
     filed with the Commission.  See Rule 13d-1(a) for other parties to whom
     copies are to be sent.

                        (Continued on following pages)

                              (Page 1 of 7 Pages)

- ------------------------
/1/       The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
                                        
          The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
 
- -----------------------                                  ---------------------
  CUSIP NO. 62936 P 103                13D                 PAGE 2 OF 7 PAGES
- -----------------------                                  ---------------------
 
- ------------------------------------------------------------------------------
      NAME OF REPORTING PERSONS                          
 1    S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
           BIOTECHNOLOGY VALUE FUND, L.P.                      
- ------------------------------------------------------------------------------

 2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   
                                                               (a) [X] (b) [ ]
- ------------------------------------------------------------------------------
 3    SEC USE ONLY

- ------------------------------------------------------------------------------

 4    SOURCE OF FUNDS*
            WC
- ------------------------------------------------------------------------------

 5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS 
      REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)                              [ ]
- ------------------------------------------------------------------------------
                                            
 6    CITIZENSHIP OR PLACE OF ORGANIZATION  
            Delaware                              
- ------------------------------------------------------------------------------
                                            
     NUMBER OF       7   SOLE VOTING POWER  
                                -0-               
      SHARES       -----------------------------------------------------------
                                              
   BENEFICIALLY      8    SHARED VOTING POWER 
                                529,400
     OWNED BY
                   -----------------------------------------------------------
       EACH                                      
                     9    SOLE DISPOSITIVE POWER 
    REPORTING                      -0-
 
      PERSON       -----------------------------------------------------------
                                                   
       WITH          10   SHARED DISPOSITIVE POWER 
                                  529,400
- ------------------------------------------------------------------------------
      
11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH               
      REPORTING PERSON                           
             529,400                              
- ------------------------------------------------------------------------------
      
12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES 
      CERTAIN SHARES*                                                      [ ]
- ------------------------------------------------------------------------------
                                                       
13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 
             4.4%
- ------------------------------------------------------------------------------
                                
14    TYPE OF REPORTING PERSON* 
             PN
- ------------------------------------------------------------------------------

                     *SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
 
- -----------------------                                  ---------------------
  CUSIP NO. 62936 P 103                13D                 PAGE 3 OF 7 PAGES
- -----------------------                                  ---------------------
 
- ------------------------------------------------------------------------------
      NAME OF REPORTING PERSONS                          
 1    S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
              BVF PARTNERS L.P.                                        
- ------------------------------------------------------------------------------

 2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   
                                                               (a) [X] (b) [ ]
- ------------------------------------------------------------------------------
 3    SEC USE ONLY

- ------------------------------------------------------------------------------

 4    SOURCE OF FUNDS*
            OO
- ------------------------------------------------------------------------------

 5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS 
      REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)                              [ ]
- ------------------------------------------------------------------------------
                                            
 6    CITIZENSHIP OR PLACE OF ORGANIZATION  
            Delaware                              
- ------------------------------------------------------------------------------
                                            
     NUMBER OF       7   SOLE VOTING POWER  
                               -0-               
      SHARES       -----------------------------------------------------------
                                              
   BENEFICIALLY      8    SHARED VOTING POWER 
                               998,900
     OWNED BY
                   -----------------------------------------------------------
       EACH                                      
                     9    SOLE DISPOSITIVE POWER 
    REPORTING                  -0-
 
      PERSON       -----------------------------------------------------------
                                                   
       WITH          10   SHARED DISPOSITIVE POWER 
                                  998,900
- ------------------------------------------------------------------------------
      
11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH               
      REPORTING PERSON                           
             998,900
- ------------------------------------------------------------------------------
      
12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES 
      CERTAIN SHARES*                                                      [ ]
- ------------------------------------------------------------------------------
                                                       
13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 
             8.3%
- ------------------------------------------------------------------------------
                                
14    TYPE OF REPORTING PERSON* 
             PN
- ------------------------------------------------------------------------------
 
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
 
- -----------------------                                  ---------------------
  CUSIP NO. 62936 P 103                13D                 PAGE 4 OF 7 PAGES
- -----------------------                                  ---------------------
 
- ------------------------------------------------------------------------------
      NAME OF REPORTING PERSONS                          
 1    S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
      BVF INC.                                                         
- ------------------------------------------------------------------------------

 2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*   
                                                               (a) [X] (b) [ ]
- ------------------------------------------------------------------------------
 3    SEC USE ONLY

- ------------------------------------------------------------------------------

 4    SOURCE OF FUNDS*
            WC, OO
- ------------------------------------------------------------------------------

 5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS 
      REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)                              [ ]
- ------------------------------------------------------------------------------
                                            
 6    CITIZENSHIP OR PLACE OF ORGANIZATION  
            Delaware                              
- ------------------------------------------------------------------------------
                                            
     NUMBER OF       7   SOLE VOTING POWER  
                               -0-               
      SHARES       -----------------------------------------------------------
                                              
   BENEFICIALLY      8    SHARED VOTING POWER 
                               998,900
     OWNED BY
                   -----------------------------------------------------------
       EACH                                      
                     9    SOLE DISPOSITIVE POWER 
    REPORTING                     -0-
 
      PERSON       -----------------------------------------------------------
                                                   
       WITH          10   SHARED DISPOSITIVE POWER 
                                 998,900
- ------------------------------------------------------------------------------
      
11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH               
      REPORTING PERSON                           
             998,900
- ------------------------------------------------------------------------------
      
12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES 
      CERTAIN SHARES*                                                      [ ]
- ------------------------------------------------------------------------------
                                                       
13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 
             8.3%
- ------------------------------------------------------------------------------
                                
14    TYPE OF REPORTING PERSON* 
             IA, CO
- ------------------------------------------------------------------------------
 
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
 
- -----------------------                                  ---------------------
  CUSIP NO. 62936 P 103                13D                 PAGE 5 OF 7 PAGES
- -----------------------                                  ---------------------

     This Amendment No. 1 (this "Amendment") relates to the Statement on
Schedule 13D (the "Statement") dated April 25, 1997, filed with the Securities
and Exchange Commission on behalf of Biotechnology Value Fund, L.P., a Delaware
limited partnership ("BVF"), BVF Partners L.P., a Delaware limited partnership
("Partners"), and BVF Inc., a Delaware corporation ("BVF Inc." and, together
with BVF and Partners, the "Reporting Persons") with respect to the Common
Stock, par value $0.001 per share (the "Stock"), of NPS Pharmaceuticals, Inc., a
Delaware corporation ("NPS"). The principal executive office of NPS is located
at 420 Chipeta Way, Suite 240, Salt Lake City, UT 84108-1256.


     Item 3 is hereby amended to read in its entirety as follows:

ITEM 3.   SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

     Since December 1, 1997, Partners, in its capacity as general partner of
BVF, has purchased on behalf of such limited partnership an aggregate number of
183,400 shares of the Stock for an aggregate consideration of $1,617,322,
utilizing funds provided by BVF from its working capital pursuant to the terms
of its limited partnership agreement with Partners.  In addition, Partners, in
its capacity as investment manager with respect to certain managed accounts, has
purchased on behalf of such managed accounts an aggregate number of 177,500
shares of the Stock for an aggregate consideration of $1,551,995 utilizing funds
under management by Partners pursuant to investment management agreements
between Partners and such managed accounts.
 
     Item 5 is hereby amended to read in its entirety as follows:

ITEM 5.   INTEREST IN SECURITIES OF THE ISSUER.

     (a) BVF beneficially owns 529,400 shares of the Stock, Partners
beneficially owns 998,900 shares of the Stock, and BVF Inc. beneficially owns
998,900 shares of the Stock, approximately 4.4%, 8.3% and 8.3%, respectively, of
the aggregate number of shares outstanding as of September 30, 1997 (as reported
in NPS's most recent quarterly statement on Form 10-Q).

     (b) BVF shares voting and dispositive power over the 529,400 shares of the
Stock it beneficially owns with Partners.  Partners and BVF Inc. share voting
and dispositive power over the 998,900 shares of the Stock they beneficially own
with, in addition to BVF, the managed accounts on whose behalf Partners, as
investment manager, purchased such shares. The managed accounts on whose behalf
Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited
liability company ("ILL10"), Palamundo, L.D.C., a limited duration company
organized under the laws of the Cayman Islands ("Palamundo"), ZPG Securities,
L.L.C., a New York limited liability company ("ZPG") and Biotechnology Value
<PAGE>
 
- -----------------------                                  ---------------------
  CUSIP NO. 62936 P 103                13D                 PAGE 6 OF 7 PAGES
- -----------------------                                  ---------------------

Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd.").   ILL10, Palamundo, ZPG
and BVF Ltd. are collectively referred to herein as the "Accounts."  The
Accounts specialize in holding biotechnology stocks for investment purposes and
the business address of each is c/o BVF Partners L.P., 333 West Wacker Drive,
Suite 1600, Chicago, Illinois 60606.

     (c) Exhibit B attached hereto contains information as to all transactions
in the Stock by the Reporting Persons during the past 60 days.  All such
transactions were made for cash in open market, over-the-counter transactions.
No other transactions in the Stock have been effected by the Reporting Persons
during the past 60 days.

     (d) The Accounts are entitled to receive dividends and any sale proceeds
with respect to the Stock in proportion to their respective ownership interests
therein.

     Item 7 is hereby amended to read in its entirety as follows:

ITEM 7.   MATERIAL TO BE FILED AS EXHIBITS.

     Exhibit A - Agreement Regarding Joint Filing

     Exhibit B - Transactions in the Stock by the Reporting Persons during the
last 60 days.
<PAGE>
 
- -----------------------                                  ---------------------
  CUSIP NO. 62936 P 103                13D                 PAGE 7 OF 7 PAGES
- -----------------------                                  ---------------------

     After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

Dated:  December 24, 1997

        BIOTECHNOLOGY VALUE FUND, L.P.

        By:  BVF Partners L.P., its general partner

             By:  BVF Inc., its general partner


                  By:    /s/ MARK N. LAMPERT
                        ---------------------------------
                        Mark N. Lampert
                        President

        BVF PARTNERS L.P.

        By:  BVF Inc., its general partner


             By:    /s/ MARK N. LAMPERT
                   -------------------------------------------
                   Mark N. Lampert
                   President

        BVF INC.


        By:    /s/ MARK N. LAMPERT
              -----------------------------------------------------
              Mark N. Lampert
              President

<PAGE>
 
                                   EXHIBIT A

                       AGREEMENT REGARDING JOINT FILING
                       --------------------------------


     The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF
Inc., a Delaware corporation, hereby agree and acknowledge that the Amendment
containing the information required by Schedule 13D, to which this Agreement is
attached as an exhibit, is filed on behalf of each of them.  The undersigned
further agree that any further amendments or supplements thereto shall also be
filed on behalf of each of them.

Dated:  December 24, 1997

     BIOTECHNOLOGY VALUE FUND, L.P.

     By:  BVF Partners L.P., its general partner

          By:  BVF Inc., its general partner


               By:    /s/ MARK N. LAMPERT
                     ---------------------------------
                     Mark N. Lampert
                     President

     BVF PARTNERS L.P.

     By:  BVF Inc., its general partner


          By:    /s/ MARK N. LAMPERT
                -------------------------------------------
                Mark N. Lampert
                President

     BVF INC.


     By:    /s/ MARK N. LAMPERT
           -----------------------------------------------------
           Mark N. Lampert
           President

<PAGE>
 
                                   EXHIBIT B

              TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS
              --------------------------------------------------
                            DURING THE LAST 60 DAYS
                            -----------------------
<TABLE>
<CAPTION>

- --------------------------------------------------------------------------------------
Settlement                  For the               Price per                          
- ----------                  -------               ---------
  Date           By        Account of   Quantity     Share     Type of Trade   Broker 
  ----           --        ----------   --------     -----     -------------   ------
======================================================================================
<S>          <C>           <C>           <C>        <C>         <C>             <C>
  12/01/97   Partners      BVF             95,000     $9.2500   Purchase        VECT
- --------------------------------------------------------------------------------------
  12/01/97   Partners      ILL10            5,000     $9.2500   Purchase        VECT
- --------------------------------------------------------------------------------------
  12/01/97   Partners      PAL             10,000     $9.2500   Purchase        VECT
- --------------------------------------------------------------------------------------
  12/01/97   Partners      BVF Ltd.        60,000     $9.2500   Purchase        VECT
- --------------------------------------------------------------------------------------
  12/15/97   Partners      BVF             25,000     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/15/97   Partners      ILL10            6,000     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/15/97   Partners      ZPG              5,000     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/15/97   Partners      BVF Ltd.        25,000     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/16/97   Partners      BVF             29,400     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/16/97   Partners      ILL10            5,000     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/16/97   Partners      PAL              3,000     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/16/97   Partners      BVF Ltd.        35,000     $8.3750   Purchase        INET
- --------------------------------------------------------------------------------------
  12/18/97   Partners      BVF              6,000     $8.2500   Purchase        COWN
- --------------------------------------------------------------------------------------
  12/18/97   Partners      ILL10            3,000     $8.2500   Purchase        COWN
- --------------------------------------------------------------------------------------
  12/18/97   Partners      PAL              2,000     $8.2500   Purchase        COWN
- --------------------------------------------------------------------------------------
  12/18/97   Partners      ZPG              2,000     $8.2500   Purchase        COWN
- --------------------------------------------------------------------------------------
  12/18/97   Partners      BVF Ltd.         7,000     $8.2500   Purchase        COWN
- --------------------------------------------------------------------------------------
  12/18/97   Partners      BVF              2,000     $8.2500   Purchase        INET
- --------------------------------------------------------------------------------------
  12/19/97   Partners      BVF             19,000     $8.2500   Purchase        INET
- --------------------------------------------------------------------------------------
  12/24/97   Partners      BVF              7,000     $8.2500   Purchase        INET
- --------------------------------------------------------------------------------------
  12/24/97   Partners      ILL10            2,000     $8.2500   Purchase        INET
- --------------------------------------------------------------------------------------
  12/24/97   Partners      ZPG              2,500     $8.2500   Purchase        INET
- --------------------------------------------------------------------------------------
  12/24/97   Partners      BVF Ltd.         5,000     $8.2500   Purchase        INET
- --------------------------------------------------------------------------------------
</TABLE> 

     VECT     =    Vector Securities
     INET     =    Instinet
     COWN     =    Cowen & Co. 


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission